Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.23
  • Today's Change-0.72 / -6.03%
  • Shares traded25.19k
  • 1 Year change-0.53%
  • Beta1.5695
Data delayed at least 15 minutes, as of Nov 11 2024 15:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

  • Revenue in USD (TTM)60.04m
  • Net income in USD-57.32m
  • Incorporated2020
  • Employees207.00
  • Location
    AVITA Medical Inc28159 Avenue Stanford, Suite 220VALENCIA 91355United StatesUSA
  • Phone+1 (661) 367-9170
  • Websitehttps://www.avitamedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zura Bio Ltd0.00-27.94m292.09m14.00--1.86-----0.4944-0.49440.002.460.00----0.00-23.00---30.30--------------0.0136-------2,050.99------
Atea Pharmaceuticals Inc0.00-176.00m295.48m75.00--0.6201-----2.10-2.100.005.640.00----0.00-30.97-5.90-32.19-6.98-------38.91----0.00-------17.30------
Biomea Fusion Inc0.00-144.01m296.43m107.00--3.90-----4.00-4.000.002.100.00----0.00-85.85---98.73--------------0.00-------43.29------
Poseida Therapeutics Inc88.46m-112.77m299.13m337.00--4.92--3.38-1.19-1.190.92960.62650.3051--7.27268,066.70-38.89-40.70-52.75-47.72-----127.48-233.49---13.140.4916---50.42---92.85--19.01--
Vanda Pharmaceuticals Inc.190.86m-16.39m302.52m203.00--0.559--1.59-0.2824-0.28243.299.290.29679.305.30940,187.20-2.556.61-2.957.6293.6290.55-8.5915.184.84----0.00-24.27-0.0496-60.02-36.96-56.77--
Tscan Therapeutics Inc12.20m-104.41m306.19m175.00--1.20--25.10-1.05-1.050.12254.820.0353----79,220.78-30.19---33.78-------855.84------0.1066--55.52---34.73------
Taysha Gene Therapies Inc12.87m-114.34m307.41m52.00--2.77--23.88-0.8987-0.89870.06430.54060.0913----247,557.70-81.11---116.01-------888.18------0.2598--517.55--32.80------
AVITA Medical Inc60.04m-57.32m310.58m207.00--25.62--5.17-2.23-2.232.330.46640.74091.537.30290,048.30-70.74---86.14--86.46---95.47--3.37-11.270.7768--45.68---32.69------
Nautilus Biotechnology Inc0.00-70.21m312.65m161.00--1.40-----0.561-0.5610.001.780.00----0.00-24.29---25.05--------------0.00-------9.93------
Mersana Therapeutics Inc29.94m-104.77m315.27m123.00--37.41--10.53-0.8648-0.86480.24690.06870.1222--38.14243,390.30-42.75-61.68-59.36-81.35-----349.98-622.19----0.7508--38.6528.3215.94--9.61--
AC Immune SA17.69m-69.13m316.61m133.00--2.25--17.89-0.7332-0.73320.19111.420.0787--28.76133,041.40-30.73-18.25-42.90-19.52-----390.68-148.29---128.010.0255--276.1415.5223.35---15.49--
Tango Therapeutics Inc43.38m-123.40m316.88m140.00--1.38--7.30-1.15-1.150.40412.130.1112----309,885.70-31.62---35.28-------284.43------0.00--46.93--5.95------
Artiva Biotherapeutics Inc-100.00bn-100.00bn318.40m82.00--------------1.09----------------------------0.0087--579.21--51.15------
Rezolute Inc0.00-68.46m323.32m59.00--2.46-----1.33-1.330.002.270.00----0.00-53.39-50.36-56.66-53.25------------0.00-------32.19------
Aldeyra Therapeutics Inc0.00-37.87m328.01m10.00--3.34-----0.6387-0.63870.001.650.00----0.00-26.89-36.79-31.76-40.77------------0.1342------39.47------
Design Therapeutics Inc0.00-50.53m330.10m57.00--1.26-----0.8982-0.89820.004.610.00----0.00-17.39---17.96--------------0.00-------5.61------
Data as of Nov 11 2024. Currency figures normalised to AVITA Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

19.45%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20241.65m6.33%
The Vanguard Group, Inc.as of 30 Jun 20241.34m5.17%
Geode Capital Management LLCas of 30 Jun 2024586.08k2.26%
SSgA Funds Management, Inc.as of 30 Jun 2024508.00k1.96%
Soleus Capital Management LP (Investment Management)as of 30 Jun 2024267.00k1.03%
Essex Investment Management Co. LLCas of 30 Sep 2024231.09k0.89%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024209.58k0.81%
Morgan Stanley & Co. LLCas of 30 Jun 202499.00k0.38%
D. E. Shaw & Co. LPas of 30 Jun 202484.83k0.33%
Legato Capital Management LLCas of 30 Sep 202479.37k0.31%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.